2 most recent filings and news items mentioning WHWK. Updated every 60 seconds.
EarningsAug 6, 2026Neutral
Whitehawk Therapeutics reported Q2 2026 financials highlighting a cash balance of $190.0 million and clinical progress. The company's progress is overshadowed by a material decrease in revenue compared to the previous year.
View filing at SEC.gov →
OtherMay 21, 2026Positive
Whitehawk Therapeutics entered into an option agreement with Hangzhou DAC for access to CPT113 for up to five additional ADC programs, with anticipated IND submissions over the next 12-24 months. The expansion validates the company's CPT113 linker-payload technology platform and
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.